Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.
The bit I cannot resolve on my own is how much of the SELECT benefit is plausibly independent of the weight loss, and whether that distinction changes anything practical.
Not looking for reassurance. Looking for the part I have got wrong.
BethLabQueen said:Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.
BethLabQueen said:...we don't know the long-term effects of cardiovascular risk...
This is a fair point, and I think intellectual honesty requires acknowledging it. GLP-1 agonists in their current form have ~8-10 years of human exposure data. That's not nothing, but it's not 30+ years either.
However: the risk-benefit calculation should also consider the KNOWN long-term effects of untreated obesity — diabetes, cardiovascular disease, cancer, joint destruction, reduced lifespan by 5-10 years.
Uncertainty about GLP-1 long-term safety vs certainty about obesity consequences. The calculus seems clear to me, but reasonable people can disagree.
Dr.RenalNash said:BethLabQueen said: ...we don't know the long-term effects of cardiovascular risk...
Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history. Results were encouraging:
- NT-proBNP: 69 pg/mL (normal, cardiac function preserved)
- Lp(a): 29 nmol/L (genetic, unchanged — expected)
- ApoB: dropped from 159 to 94 mg/dL (excellent response)
- Coronary calcium score: 0 (unchanged from baseline — reassuring)
The ApoB reduction is particularly meaningful — it's considered the best single predictor of cardiovascular risk. GLP-1 therapy seems to improve this consistently.
Janoshik Analytical — Independent Testing
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesGL Biochem (Shanghai) Ltd. — Direct Manufacturer
Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemBethLabQueen said:Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.
This is my experience too, for whatever a second data point is worth. The detail I would add is minor and it is already implied above.
Clinical perspective, offered as context rather than as advice.
Metabolic syndrome resolution on cardiovascular risk: I went from meeting 5 of 5 diagnostic criteria to meeting ZERO after 10 months of treatment.
The 5 criteria (and my journey):
- Waist circumference: 49" → 35" ✅ Resolved
- Triglycerides: 233 → 103 ✅ Resolved
- HDL: 33 → 55 ✅ Resolved
- Blood pressure: 143/91 → 121/75 ✅ Resolved
- Fasting glucose: 128 → 85 ✅ Resolved
Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.